Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 6/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.44 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.43 |
| ▸ | RAMP3 | O60896 | 5/20 | 0.42 |
| ▸ | CALCR | P30988 | 5/20 | 0.42 |
| ▸ | NMUR2 | Q9GZQ4 | 2/20 | 0.42 |
| ▸ | NMUR1 | Q9HB89 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30104718 | 0.98 | CXCR4 (0.46) | CXCR4OPRM1OPRD1EPHA2RAMP3 | |
| SCHEMBL29864852 | 0.92 | OPRM1 (0.51) | CXCR4OPRM1OPRD1EPHA2RAMP3 | |
| SCHEMBL29864927 | 0.92 | OPRM1 (0.51) | CXCR4OPRM1OPRD1EPHA2RAMP3 | |
| SCHEMBL29864866 | 0.92 | OPRM1 (0.51) | CXCR4OPRM1OPRD1EPHA2RAMP3 | |
| SCHEMBL9293866 | 0.92 | NMUR2 (0.50) | CXCR4OPRM1OPRD1EPHA2RAMP3 | |
| SCHEMBL12680175 | 0.91 | CXCR4 (0.45) | CXCR4OPRM1OPRD1EPHA2RAMP3 | |
| SCHEMBL2790805 | 0.91 | CXCR4 (0.45) | CXCR4OPRM1OPRD1EPHA2RAMP3 | |
| SCHEMBL2790798 | 0.91 | CXCR4 (0.45) | CXCR4OPRM1OPRD1EPHA2RAMP3 | |
| SCHEMBL8628213 | 0.91 | CXCR4 (0.46) | CXCR4OPRM1OPRD1EPHA2RAMP3 | |
| SCHEMBL8382696 | 0.90 | CXCR4 (0.45) | CXCR4OPRM1OPRD1EPHA2RAMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220378950-A1 | COMPOUNDS HAVING RD TARGETING MOTIFS AND METHODS OF USE THEREOF | WASHINGTON UNIVERSITY | 2022-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220378950-A1 | COMPOUNDS HAVING RD TARGETING MOTIFS AND METHODS OF USE THEREOF | DDR1, CD47, ILK | CXCR4 63/4885OPRM1 2416/4885OPRD1 2622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.